Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyFidelis Care oncology prior auth Policy Update | O…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentFidelis CarePolicy N/A

    Oncology medications and supportive agents prior authorization

    Customize your policy alerts

    Sign up for all Fidelis Care policy alerts

    Know when Fidelis Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Evolent review and prior authorization requirements for oncology medications and supportive agents for Fidelis Care Essential Plan and Qualified Health Plans (members 18+; pediatric membership added 7/1/2022). Applies to dispensing at pharmacy or administration in physician office, outpatient hospital, or ambulatory settings.

    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 1, 2022
    Next Review DateN/A
    Key ActionSubmit the entire oncology regimen to Evolent via the web portal or phone; obtain prior authorization before dispensing or administration.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~150HCPCS/Q-codes listed
    18+Member age coverage
    RequiredRegimen submission
    ListedOut-of-scope categories

    Coverage Preconditions and Scope

    Prior authorization coverage preconditions

    Covered when ALL of the following are met

    Operational prerequisites: 1) The drug is one of those listed by HCPCS/J-code in this document; 2) The provider submits the entire oncology regimen to Evolent via the web portal (my.newcenturyhealth.com) or by calling 1-888-999-7713, option 1; 3) Evolent review/authorization is obtained prior to dispensing or administration.

    Pediatric membership inclusion effective 7/1/2022; clinical trials may be submitted for review effective 7/1/2022.

    The following request types are out of scope for submission to Evolent and should not be sent for prior authorization or review: Antibiotics; Bone marrow/stem cell transplants and CAR-T cell therapy; Cablivi; Controlled substances; Equipment requests (infusion pumps); Genetic laboratory testing and laboratory services; Hemophilia drugs; Immune globulins; Inpatient drug requests; Iron preparations; Pain medications; Radiopharmaceuticals; Surgeries/surgical procedures; and Sickle cell diagnoses.

    RequirementDetails
    Requirement to submit full regimen
    All oncology regimens composed of agents listed in this document must have the entire regimen submitted to Evolent for review. Omission of any drug in the oncology regimen submission may result in a denial.
    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 1, 2022
    Next Review DateN/A
    Key ActionSubmit the entire oncology regimen to Evolent via the web portal or phone; obtain prior authorization before dispensing or administration.
    SourceLink
    On This Page
    Coverage Preconditions and ScopeHCPCS / J- / Q-code ListingsAuthorization, Submission & Billing RequirementsPolicy Background and Scope Notes

    HCPCS / J- / Q-code Listings

    Listed HCPCS/J-codes and agentsHCPCSCovered
    C9174DATOPOTAMAB DERUXTECAN-DLNK (DATROWAY)
    J0897J0897
    C9175TREOSULFAN (GRAFAPEX)
    J1010J1010
    C9293GLUCARPIDASE
    J1246J1246
    J0185APREPITANT INJECTION
    J0207AMIFOSTINE 500 MG INJ
    J0208SODIUM THIOSULFATE
    J0594BUSULFAN 1 MG INJ
    1–10 of 97
    1/10
    Listed J-codes (partial)HCPCSCovered
    J9298NIVOLUMAB 240MG-RELALTIMAB 80MG INJ
    J9299NIVOLUMAB
    J9301OBINUTUZUMAB
    J9302OFATUMUMAB INJECTION
    J9303INJECTION PANITUMUMAB 10 MG
    J9304PEMETREXED INJECTION
    J9305INJECTION PEMETREXED 10 MG
    J9306PERTUZUMAB
    J9307INJECTION PRALATREXATE 1 MG
    J9308RAMUCIRUMAB
    1–10 of 32
    1/4
    Listed J-codes (continued)HCPCSCovered
    J9347RETIFANLIMAB-DLWR INJ
    J9348TREMELIMUMAB-ACTL INJECTION (IMJUDO)
    J9349NAXITAMAB-GQGK INJECTION
    J9350TAFASITAMAB-CXIX
    J9351MOSUNETUZUMAB-AXGB INJECTION
    J9352TOPOTECAN 0.1 MG INJ
    J9353TRABECTEDIN
    J9354MARGETUXIMAB-CMKB
    J9355ADO-TRASTUZUMAB EMTANSINE
    J9356INJECTION TRASTUZUMAB 10 MG
    Listed J-codes (continued)HCPCSCovered
    J9357TRASTUZUMAB/HYALURONIDASE-OYSK
    J9358INJECTION VALRUBICIN INTRAVESICAL
    J9359FAM-TRASTUZUMAB DERUXTECAN-NXKI
    J9360LONCASTUXIMAB TESIRINE-LPYL
    J9361INJECTION VINBLASTINE SULFATE 1 MG
    J9370INJECTION, EFBEMALENOGRASTIM ALFAVUXW
    J9371VINCRISTINE SULFATE 1 MG
    J9380VINCRISTINE LIPOSOMAL
    J9382TECLISTAMAB-CQYV INJECTION (TECVAYLI)
    J9390ZENOCUTUZUMAB-ZBCO (BIZENGRI)
    1–10 of 16
    1/2
    J9999 miscellaneous drug entriesHCPCSCovered
    J9999Multiple entries for miscellaneous/injectable drugs (e.g., BEXAROTENE 1% TOPICAL GEL; DOCETAXEL (DOCIVYX); FLUOROURACIL topical formulations; IMIQUIMOD; MELPHALAN INJ; PEGINTERFERON, etc.)
    Listed Q-codes and biologic biosimilarsHCPCSCovered
    Q0155DRONABINL ORAL (SYNDROS)
    Q2017TENIPOSIDE 50 MG
    Q2043
    Q2050SIPULEUCEL-T AUTO CD5+
    Q5101LIPOSOMAL DOXORUBICIN
    Q5106FILGRASTIM-SNDZ
    Q5107EPOETIN ALFA-EPBX (RETACRIT BIOSIMILAR)
    Q5108BEVACIZUMAB - AWWB
    Q5110PEGFILGRASTIM-JMDB
    Q5111FILGRASTIM-AAFI (NIVESTYM BIOSIMILAR)
    1–10 of 29
    1/3

    Authorization, Submission & Billing Requirements

    Documentation Required

    How to submit and required content

    Oncology drugs and supportive agents listed in this policy require prior authorization through Evolent. Submit requests via Evolent's web portal (my.newcenturyhealth.com) or by phone at 1-888-999-7713, option 1. Include the full oncology regimen (all agents, supportive medications, and exact dosing) when you submit; omission of any drug in the regimen may result in a denial.

    • Submit the entire oncology regimen regardless of individual drug PA status — omissions may result in denial.
    • Submission methods: Evolent web portal (my.newcenturyhealth.com) or phone 1-888-999-7713, option 1.
    • Required content: member demographics, clinical indication/diagnosis, full regimen including all agents (drug names and doses), treatment start date, prior therapies, relevant labs/imaging, and supporting clinical notes.
    Denial Risk

    Code mismatch denial risk

    Billing must use the precise HCPCS/J/Q code that corresponds to the administered drug. If the claim is billed with a HCPCS code that does not match the drug listed on the prior authorization (or with an unlisted/non-specific code), the claim may be denied.

    • Always submit the exact HCPCS/J/Q code for the administered product on both the prior authorization request and the claim.
    • If a product is reported under a generic or unlisted HCPCS (e.g., J9999) without clear linkage to the prior auth documentation, expect increased denial risk.
    Billing Rule

    Provider actions & billing requirements

    Providers must ensure regimen completeness and coding accuracy when requesting authorization and when billing. Prior authorization applies to the oncology HCPCS/J/Q codes listed in this policy; verify the code(s) submitted for authorization match the code(s) billed.

    • Regimen completeness: include every drug in the treatment regimen on the PA submission — missing agents can cause claim or PA denial.
    • Coding documentation: include the precise HCPCS/J/Q code for each administered drug on the PA request and on the claim.
    • Prior authorization requirement: listed oncology drugs/supportive agents are subject to Evolent prior auth for members (effective 2022-07-01).

    Policy Background and Scope Notes

    This policy defines the operational prior authorization and review processes for oncology medications and supportive agents administered in outpatient settings or dispensed at pharmacy for Fidelis Care members. Providers must submit the entire oncology regimen to Evolent for review; omission of any drug in the regimen may result in denial. The review process is limited to administrative and authorization determinations for the listed agents and does not provide disease-specific clinical treatment guidance.

    Prior authorization and review are not intended to cover items explicitly listed as out of scope (see out-of-scope list). For drugs that are included in the document, providers must follow the submission procedures and supply the complete regimen and the precise HCPCS/J/Q codes for the agents to support authorization and claims processing.